T. Rowe Price Investment Management, Inc., a registered investment adviser, initiated a new position in Abbott Laboratories (NYSE:ABT) during Q4 2025, according to its most recent 13F filing with the Securities and Exchange Commission.
The institutional investor purchased 17,887,109 shares of the Healthcare company, valued at approximately $2.2B as of the filing date.
Abbott Laboratories's stock currently trades at $112.94 with a market capitalization of $214.5B.